iOnctura
PrivateLast Round
Series B
Jun 20, 2024
Est. Valuation
$139.6M
Total Funding Raised
$111.26M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
iOnctura operates in Healthcare & Life Sciences and is based in Geneva. Its latest recorded funding round was a Series B round in June 2024.
iOnctura is a biotechnology company focused on developing next-generation bio-molecules for the treatment of cancer and fibrosis through innovative therapeutics that target immunosuppression in the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iOnctura Comparables
Compare iOnctura with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rhizen Pharmaceuticals AG | 81% | |
| Secura Bio | 72% | |
| Anaveon | 71% |
For institutional investors. Book with your work email.
iOnctura Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 20, 2024 | ||||
| Grant | Dec 20, 2022 | ||||
| Debt | Sep 28, 2022 | ||||
| Series A Extension | Jul 14, 2020 | ||||
| Series A | Jan 23, 2020 | ||||
Seed | Jun 20, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iOnctura Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, Series B |
| XGEN Venture | Series B |
| Syncona | Series B |
| Fongit | Debt |
| 3B FUTURE Health Fund | Series B, Series A Extension |
| M Ventures | Series A, Series B |
| VI Partners | Series B, Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 969% MoM, from 29 to 310.
- Jan 9, 2026
CEO to present at the 2026 J.P. Morgan Healthcare Conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
iOnctura BV attends the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Arizona on Nov 6th '26 and presents late-breaking PULMO-01 data on roginolisib combinations in immunotherapy-resistant NSCLC.
- attends_eventOct 29, 2026
iOnctura BV is set to present a late-breaking poster evaluating roginolisib in patients with immunotherapy-resistant non-small cell lung cancer at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Arizona on Nov 6th '26.
- is_developingOct 16, 2026
On Oct 16th '26, iOnctura BV prepares roginolisib for late-stage development, with randomized studies in uveal melanoma and lung cancer fully enrolled.
- hiresOct 15, 2026
iOnctura BV appoints Paul Sekhri as Chair of its Board of Directors with immediate effect in Switzerland, the Netherlands and Massachusetts on Oct 15th '26.
For institutional investors. Book with your work email.
iOnctura Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iOnctura's valuation, stock price, and market status.
Is iOnctura a public or private company?
iOnctura is a private company.
What is the current stock price of iOnctura?
iOnctura is a private company, so its shares have no public market price. Caplight tracks iOnctura's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iOnctura worth (valuation)?
iOnctura's valuation is estimated at $139.6M based on funding round data.
Can I buy iOnctura stock?
iOnctura shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iOnctura's last funding round?
iOnctura's most recent funding round was Series B on June 20, 2024.
Who are the main investors in iOnctura?
Key investors in iOnctura include Syncona, 3B FUTURE Health Fund, VI Partners, Inkef Capital, Syncona Limited.
Will iOnctura IPO soon?
No public IPO plans have been announced for iOnctura.
How can I track iOnctura secondary market activity?
Caplight tracks bids, offers, and trades in iOnctura's shares on secondary markets.